A phase II study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) or Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to imatinib.

Michel Zwaan,Linda C. Stork,Yves Bertrand,Lia Gore,Nobuko Hijiya,Carmino Antonio de Souza,Maria Lúcia de Martino Lee,M. Brigid Bradley-Garelik,Pamela R. Kearns

A phase II study of dasatinib therapy in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) or Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to imatinib.

2012

Michel Zwaan
Linda C. Stork
Yves Bertrand
Lia Gore
Nobuko Hijiya
Carmino Antonio de Souza
Maria Lúcia de Martino Lee
M. Brigid Bradley-Garelik
Pamela R. Kearns

TPS9594 Background: Dasatinib is a BCR-ABL inhibitor approved for treatment in adult patients (pts) with newly diagnosed Ph+ CML-CP; CML resistant/intolerant to prior therapy, including imatinib; a...

Keywords:

Pathology
Phases of clinical research
Imatinib
Philadelphia Chromosome Positive
Chronic phase chronic myelogenous leukemia
Oncology
Medicine
Dasatinib
Internal medicine
newly diagnosed

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations